1. Home
  2. UFCS vs GERN Comparison

UFCS vs GERN Comparison

Compare UFCS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

HOLD

Current Price

$44.22

Market Cap

936.4M

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFCS
GERN
Founded
1946
1990
Country
United States
United States
Employees
N/A
258
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
936.4M
808.3M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
UFCS
GERN
Price
$44.22
$1.26
Analyst Decision
Buy
Hold
Analyst Count
2
3
Target Price
$40.50
$2.17
AVG Volume (30 Days)
107.8K
13.9M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
2.01%
N/A
EPS Growth
87.45
N/A
EPS
1.15
N/A
Revenue
$1,386,412,000.00
N/A
Revenue This Year
$11.80
$26.91
Revenue Next Year
$8.77
$43.75
P/E Ratio
$38.63
N/A
Revenue Growth
10.62
N/A
52 Week Low
$25.81
$1.04
52 Week High
$49.94
$2.01

Technical Indicators

Market Signals
Indicator
UFCS
GERN
Relative Strength Index (RSI) 46.99 34.40
Support Level $36.27 $1.22
Resistance Level $49.94 $1.29
Average True Range (ATR) 1.46 0.06
MACD -0.67 -0.00
Stochastic Oscillator 0.87 21.15

Price Performance

Historical Comparison
UFCS
GERN

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: